Cargando…

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab

A significant barrier to effective immune clearance of cancer is loss of antitumor cytotoxic T cell activity. Antibodies to block pro-apoptotic/downmodulatory signals to T cells are currently being tested. Because invariant natural killer T cells (iNKT) can regulate the balance of Th1/Th2 cellular i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibarrondo, F. Javier, Yang, Otto O., Chodon, Thinle, Avramis, Earl, Lee, Yohan, Sazegar, Hooman, Jalil, Jason, Chmielowski, Bartosz, Koya, Richard C., Schmid, Ingrid, Gomez-Navarro, Jesus, Jamieson, Beth D., Ribas, Antoni, Comin-Anduix, Begoña
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805549/ https://www.ncbi.nlm.nih.gov/pubmed/24167550 http://dx.doi.org/10.1371/journal.pone.0076829

Ejemplares similares

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products
por: Nowicki, Theodore S., et al.
Publicado: (2018)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2008)

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Tremelimumab
Publicado: (2012)

CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
por: Niehr, Franziska, et al.
Publicado: (2011)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

A rare population of tumor antigen-specific CD4(+)CD8(+) double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
por: Matsuzaki, Junko, et al.
Publicado: (2019)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
por: Ribas, Antoni, et al.
Publicado: (2012)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
por: Spethmann, Sebastian, et al.
Publicado: (2014)

An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023)

Melanoma whole exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
por: Shi, Hubing, et al.
Publicado: (2012)

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
por: Zhou, Jing, et al.
Publicado: (2018)

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8(+) T‑cells from GzmB mediated self‑destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Tcf-1 protects anti-tumor TCR-engineered CD8(+) T-cells from GzmB mediated self-destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
por: Frankiw, Luke, et al.
Publicado: (2023)

Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
por: Ahmed, Zunirah, et al.
Publicado: (2023)

CXCR6 by increasing retention of memory CD8(+) T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
por: Muthuswamy, Ravikumar, et al.
Publicado: (2021)

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
por: Santa-Maria, Cesar August, et al.
Publicado: (2018)

Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
por: He, Mengnan, et al.
Publicado: (2017)

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
por: Campbell, Matthew T., et al.
Publicado: (2021)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
por: Capdevila, J., et al.
Publicado: (2023)

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
por: Gilbert, Jill, et al.
Publicado: (2015)

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
por: Escuin-Ordinas, Helena, et al.
Publicado: (2021)

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
por: Mahmood, Syed S., et al.
Publicado: (2018)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e69hfn6q4bt8km1c12r3o12j30